Navigation Links
New Study Shows the Use of MEDIHONEY(TM) Wound & Burn Dressing is Associated With Reduction in Wound Size
Date:4/8/2008

International Wound Journal article cites pH modulation as a key method of

action

PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Derma Sciences Inc (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that the most recent study involving MEDIHONEY(TM) Wound & Burn Dressing shows that use of the dressings are associated with a reduction in wound size, possibly driven in part by a significant reduction in overall wound pH. The 20-patient study will be published in the May edition of the International Wound Journal. The article -- "The impact of Manuka honey dressings on the surface pH of chronic wounds" -- was written by Georgina T. Gethin, Seamus Cowman and Ronan Conroy, all of the Royal College of Surgeons, Dublin, Ireland. The May edition of the International Wound Journal is a special edition of this globally-recognized peer-reviewed journal, and will be distributed to the attendees of the upcoming World Union of Wound Healing Societies conference, to be held in Toronto this June 4-8.

According to the abstract for the article, the authors evaluated the progression of 20 non-healing ulcers of various etiologies following application of the dressings over a period of two weeks. The dressings were provided by Derma Sciences' global commercialization partner, Comvita New Zealand, Inc. The authors cite their rationale for researching pH modulation in chronic wounds as follows:

"Chronic non-healing wounds have an elevated alkaline environment. The acidic pH of Manuka honey makes it a potential treatment for lowering wound pH, but the duration of the effect is unknown. Lowering wound pH can potentially reduce protease activity, increase fibroblast activity and increase oxygen release, consequently aiding wound healing."

After two weeks of treatment with the dressings, the authors concluded that, for this group of previously non-healing ulcers, "the use of Manuka honey dressings was associated with a statistically significant decrease in wound pH and a reduction in wound size." Significant wound progression during a two-week period is noted as a strong predictor of good wound healing outcomes.

Commenting on the article, Derma Sciences CEO Edward Quilty said, "Method of action is obviously an important component to having a better understanding of a medical device. Based on the results clinicians have seen all over the world, and recently here since our launch in the US and Canada, we have known for quite some time that the dressings work. Now we are getting a better understanding as to 'why'. Providing the answer to this question will no doubt increase product usage, as it makes clinicians feel more comfortable that the product has been studied thoroughly, it is effective, and we understand why it is effective. Although pH modulation and the product's high osmolarity have long been thought to contribute to the effectiveness of the product, it is rewarding to see these beliefs are being confirmed through good, well structured trials."

He also added, "This is yet another important study focused on non-healing or recalcitrant wounds that are not progressing with other advanced wound care modalities. It will only help to improve MEDIHONEY(TM)'s growing reputation as an effective dressing to 'kick-start' the healing process. This is what clinicians are reporting to us after their lengthy clinical evaluations. As we planned, we believe clinicians are gaining significant confidence in our dressing for very troublesome wounds. Once this is established in the market, it then becomes only a matter of time before the dressing is more commonly used even from the onset of a wound. This will be reflected in growing product sales as we ramp up throughout 2008 and into 2009."

About Derma Sciences

Derma Sciences is a manufacturer and marketer of advanced wound-care products, with operations based in the US and Canada, and sales worldwide. The company recently launched its MEDIHONEY(TM) Wound & Burn dressings with Active Leptospermum Honey. The Company has also obtained FDA clearance to market and sell its MOBILITY1(TM) boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

About the International Wound Journal

International Wound Journal (IWJ) is a multi-disciplinary forum providing the best quality information, research data and education on all aspects of wounds and wound healing in the fields of surgery, dermatology, oncology, nursing, radiotherapy, physiotherapy, and podiatry. Peer-reviewed, the Journal is the primary information resource for all healthcare professionals caring for patients with wound infections, the diabetic foot, leg ulcers and chronic wounds. The Editorial Team represents the full spectrum of health professionals involved in the care of patients with wounds, ensuring only the most current and comprehensive research impacting on patient care is published. Reflecting the international nature of the Journal, all key abstracts are translated into French, German, Italian, Spanish and Swedish. IWJ is indexed by MEDLINE and CINAHL. Information on the journal can be found at http://www.blackwellpublishing.com/journal.asp?ref=1742-4801&site=1.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com Brian Kennedy (media)

(609) 514-4744 brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study Shows the Personal Touch Is Key to Maintaining Weight Loss
2. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
3. ASCRS to participate in and co-fund study on post-lasik quality of life with US FDA
4. New study finds adverse effects of estrogen replacement therapy are related to the dose
5. Geisinger study: Use of digital health records improve health of the elderly
6. Occupational therapists use Wii for Parkinsons study
7. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
8. Animal Study Links Social Standing With Drug Use Risk
9. Study Shows Anger Has Its Uses
10. 1st US study -- gymnastics lands thousands in ER
11. Study finds economic burden of health insurance increasing for small employers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: